Cargando…

Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19

BACKGROUND: Patients with severe coronavirus disease 2019 (COVID-19) develop acute respiratory distress and multi-system organ failure and are associated with poor prognosis and high mortality. Thus, there is an urgent need to identify early diagnostic and prognostic biomarkers to determine the risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Guohui, Gan, Xing, Wu, Zhiqiang, Xie, Dan, Xiong, Yan, Hua, Lin, Zhou, Bing, Zhou, Nanjin, Xiang, Jie, Li, Junming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532789/
https://www.ncbi.nlm.nih.gov/pubmed/33045571
http://dx.doi.org/10.1016/j.intimp.2020.107065
_version_ 1783589998093664256
author Xue, Guohui
Gan, Xing
Wu, Zhiqiang
Xie, Dan
Xiong, Yan
Hua, Lin
Zhou, Bing
Zhou, Nanjin
Xiang, Jie
Li, Junming
author_facet Xue, Guohui
Gan, Xing
Wu, Zhiqiang
Xie, Dan
Xiong, Yan
Hua, Lin
Zhou, Bing
Zhou, Nanjin
Xiang, Jie
Li, Junming
author_sort Xue, Guohui
collection PubMed
description BACKGROUND: Patients with severe coronavirus disease 2019 (COVID-19) develop acute respiratory distress and multi-system organ failure and are associated with poor prognosis and high mortality. Thus, there is an urgent need to identify early diagnostic and prognostic biomarkers to determine the risk of developing serious illness. METHODS: We retrospectively analyzed 114 patients with COVID-19 at the Jinyintan Hospital, Wuhan based on their clinical and laboratory data. Patients were categorized into severe and mild to moderate disease groups. We analyzed the potential of serological inflammation indicators in predicting the severity of COVID-19 in patients using univariate and multivariate logistic regression, receiver operating characteristic curves, and nomogram analysis. The Spearman method was used to understand the correlation between the serological biomarkers and duration of hospital stay. RESULTS: Patients with severe disease had reduced neutrophils and lymphocytes; severe coagulation dysfunction; altered content of biochemical factors (such as urea, lactate dehydrogenase); elevated high sensitivity C-reactive protein levels, neutrophil–lymphocyte, platelet-lymphocyte, and derived neutrophil–lymphocyte ratios, high sensitivity C-reactive protein-prealbumin ratio (HsCPAR), systemic immune-inflammation index, and high sensitivity C-reactive protein-albumin ratio (HsCAR); and low lymphocyte-monocyte ratio, prognostic nutritional index (PNI), and albumin-to-fibrinogen ratio. PNI, HsCAR, and HsCPAR correlated with the risk of severe disease. The nomogram combining the three parameters showed good discrimination with a C-index of 0.873 and reliable calibration. Moreover, HsCAR and HsCPAR correlated with duration of hospital stay. CONCLUSION: Taken together, PNI, HsCAR, and HsCPAR may serve as accurate biomarkers for the prediction of disease severity in patients with COVID-19 upon admission/hospitalization.
format Online
Article
Text
id pubmed-7532789
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-75327892020-10-05 Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19 Xue, Guohui Gan, Xing Wu, Zhiqiang Xie, Dan Xiong, Yan Hua, Lin Zhou, Bing Zhou, Nanjin Xiang, Jie Li, Junming Int Immunopharmacol Article BACKGROUND: Patients with severe coronavirus disease 2019 (COVID-19) develop acute respiratory distress and multi-system organ failure and are associated with poor prognosis and high mortality. Thus, there is an urgent need to identify early diagnostic and prognostic biomarkers to determine the risk of developing serious illness. METHODS: We retrospectively analyzed 114 patients with COVID-19 at the Jinyintan Hospital, Wuhan based on their clinical and laboratory data. Patients were categorized into severe and mild to moderate disease groups. We analyzed the potential of serological inflammation indicators in predicting the severity of COVID-19 in patients using univariate and multivariate logistic regression, receiver operating characteristic curves, and nomogram analysis. The Spearman method was used to understand the correlation between the serological biomarkers and duration of hospital stay. RESULTS: Patients with severe disease had reduced neutrophils and lymphocytes; severe coagulation dysfunction; altered content of biochemical factors (such as urea, lactate dehydrogenase); elevated high sensitivity C-reactive protein levels, neutrophil–lymphocyte, platelet-lymphocyte, and derived neutrophil–lymphocyte ratios, high sensitivity C-reactive protein-prealbumin ratio (HsCPAR), systemic immune-inflammation index, and high sensitivity C-reactive protein-albumin ratio (HsCAR); and low lymphocyte-monocyte ratio, prognostic nutritional index (PNI), and albumin-to-fibrinogen ratio. PNI, HsCAR, and HsCPAR correlated with the risk of severe disease. The nomogram combining the three parameters showed good discrimination with a C-index of 0.873 and reliable calibration. Moreover, HsCAR and HsCPAR correlated with duration of hospital stay. CONCLUSION: Taken together, PNI, HsCAR, and HsCPAR may serve as accurate biomarkers for the prediction of disease severity in patients with COVID-19 upon admission/hospitalization. Elsevier B.V. 2020-12 2020-10-03 /pmc/articles/PMC7532789/ /pubmed/33045571 http://dx.doi.org/10.1016/j.intimp.2020.107065 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Xue, Guohui
Gan, Xing
Wu, Zhiqiang
Xie, Dan
Xiong, Yan
Hua, Lin
Zhou, Bing
Zhou, Nanjin
Xiang, Jie
Li, Junming
Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19
title Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19
title_full Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19
title_fullStr Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19
title_full_unstemmed Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19
title_short Novel serological biomarkers for inflammation in predicting disease severity in patients with COVID-19
title_sort novel serological biomarkers for inflammation in predicting disease severity in patients with covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532789/
https://www.ncbi.nlm.nih.gov/pubmed/33045571
http://dx.doi.org/10.1016/j.intimp.2020.107065
work_keys_str_mv AT xueguohui novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19
AT ganxing novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19
AT wuzhiqiang novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19
AT xiedan novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19
AT xiongyan novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19
AT hualin novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19
AT zhoubing novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19
AT zhounanjin novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19
AT xiangjie novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19
AT lijunming novelserologicalbiomarkersforinflammationinpredictingdiseaseseverityinpatientswithcovid19